A surge of buyout activity could produce more frenzied deals.
The longtime partners may finally tie the knot.
Each of these high-risk, high-potential stocks has the added plus of insiders making large purchases.
The two firms call Roche's second takeover bid undervalued.
The biotech has brighter prospects than its valuation suggests.
Despite some short-term concerns, this biotech is setting the stage for long-term success.
This biotech company shows strong fundamentals while technically poised to break out to new highs.
VIDEO ON MSN MONEY
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.
MONEY & POLITICS
Breaking up big banks is an untested solution to the too big to fail problem that attempts to isolate and dismantle large, troubled institutions while protecting the rest of the economy.
Joe Cantrell says he faces charges after trying to take advantage of the retailer's policy.
The IRS is struggling to combat identify thieves who file fraudulent tax returns in the names of older residents who don't need to file.